ACH-CANDESARTAN TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
12-04-2017
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
CANDESARTAN CILEXETIL
から入手可能:
ACCORD HEALTHCARE INC
ATCコード:
C09CA06
INN（国際名）:
CANDESARTAN
投薬量:
8MG
医薬品形態:
TABLET
構図:
CANDESARTAN CILEXETIL 8MG
投与経路:
ORAL
パッケージ内のユニット:
30/100
処方タイプ:
Prescription
治療領域:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
製品概要:
Active ingredient group (AIG) number: 0135220002; AHFS:
認証ステータス:
APPROVED
承認日:
2012-02-02
製品の特徴
Page 1 of 38
PRODUCT MONOGRAPH
ACH-CANDESARTAN
Candesartan Cilexetil
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AIMIPENEM AND CILASTATIN FOR INJECTION T
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
March 30, 2017
Submission Control Number: 203995
Page 2 of 38
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
..........................................................................................................
8
DRUG INTERACTIONS
........................................................................................................
14
DOSAGE AND ADMINISTRATION
....................................................................................
17
OVERDOSAGE
.......................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................ 20
STORAGE AND STABILITY
................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 23
PART II: SCIENTIFIC INFORMATION
................................................................................
24
PHARMACEUTICAL INFORMATION
..............................................................................
24
CLINICAL TRIALS
.......................................................................
完全なドキュメントを読む
